Mayflower Financial Advisors, LLC Blueprint Medicines Corp Transaction History

Mayflower Financial Advisors, LLC

  • $629 Million
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 13, 2023
SELL
$42.2 - $66.37 $506 - $796
-12 Reduced 0.18%
6,817 $430,000
Q1 2023

Apr 12, 2023
BUY
$37.97 - $50.0 $949 - $1,250
25 Added 0.37%
6,829 $307,000
Q4 2022

Jan 25, 2023
BUY
$41.06 - $66.48 $279,372 - $452,329
6,804 New
6,804 $0
Q3 2022

Oct 19, 2022
BUY
$49.93 - $77.7 $340,173 - $529,370
6,813 New
6,813 $449,000
Q2 2022

Jul 15, 2022
SELL
$45.23 - $70.15 $17,775 - $27,568
-393 Reduced 5.46%
6,806 $344,000
Q3 2021

Oct 26, 2021
BUY
$80.98 - $109.47 $582,975 - $788,074
7,199 New
7,199 $738,000

Others Institutions Holding BPMC

# of Institutions
351
Shares Held
60.3M
Call Options Held
2.25M
Put Options Held
1.18M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Mayflower Financial Advisors, LLC Portfolio

Follow Mayflower Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mayflower Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mayflower Financial Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email